



# **Microwave-Assisted Synthesis Utilizing Supported Reagents: Rapid & Versatile Synthesis of Pharmaceutically Relevant Molecules**

**Paul Humphries**  
**Pfizer Global R&D, Groton, CT**

---



# Outline

---

- (i) High Speed Celebrex® Analogue Synthesis
  - (ii) Evaluation of Encapsulated Pd Catalysts
  - (iii) Project A - Utilization of Silica-Based Reagents For Piperidine Elaborations
  - (iv) Project B - Elaboration of 2-Chloro pyridines
-




# Introduction to Celebrex®

---

Arthritis currently affects >43 million people with symptoms such as pain, inflammation and stiffness in the joints.

Celebrex® is the first COX-2 specific inhibitor approved for treating a broad range of painful conditions such as osteoarthritis, rheumatoid arthritis and acute pain.





# Silica-Based Reagents & Samplers

## Samplers

Si-Based Scavengers —  
Si-TsOH

Uniform particle size distribution facilitates filtration and bed stability.


Thermally Stable - compatible with microwave synthesis.

High surface area improves capacity and reactivity.

## Catch and Release Method


Retain product.

Retain impurities.






# Synthesis of Celebrex<sup>®</sup> Analogues





# Aryl Amination Optimization




Ligand	Base	Conditions			Product Results
		Method	Temp (°C)	Time	
DPPF	$\text{NaO}^t\text{Bu}$	Thermal	100	4 hrs	40%
DPPF	$\text{NaO}^t\text{Bu}$	Microwave	170	3 hrs	No Product
DPPF	$\text{Cs}_2\text{CO}_3$	Microwave	170	40 min	No Product
BINAP	$\text{NaO}^t\text{Bu}$	Microwave	170	4 hrs	45%
<b><math>\text{HBF}_4-\text{P}^t(\text{Bu})_3</math></b>	<b><math>\text{NaO}^t\text{Bu}</math></b>	<b>Microwave</b>	<b>170</b>	<b>30 min</b>	<b>45%</b>
$\text{HBF}_4-\text{P}^t(\text{Bu})_3$	$\text{Cs}_2\text{CO}_3$	Microwave	170	10 min	43%
$\text{HBF}_4-\text{P}^t(\text{Bu})_3$	$\text{NaO}^t\text{Bu}$	Thermal	100	24 hrs	No Product
<b><math>\text{HBF}_4-\text{P}^t(\text{Bu})_3</math></b>	<b><math>\text{Cs}_2\text{CO}_3</math></b>	<b>Thermal</b>	<b>100</b>	<b>8 hrs</b>	<b>65%</b>

Hartwig, J. F. *et al. Angew. Chem. Int. Ed.* **1998**, *37*, 2090.

Buchwald, S. L. *et al. Acc. Chem. Res.* **1998**, *31*, 805.




# Enolate Reaction Optimization



Base	Solvent	Conditions			Yield (%)
		Method	Temp (°C)	Time	
25% NaOMe	MTBE	Thermal	25	14 hrs	25
<b>NaH (60% in oil)</b>	<b>DMF</b>	<b>Thermal</b>	<b>25</b>	<b>5 days</b>	<b>88</b>
NaH (60% in oil)	DME	Thermal	100	2 hrs	60
<b>NaH (60% in oil)</b>	<b>DME</b>	<b>Microwave</b>	<b>160</b>	<b>10 min</b>	<b>95</b>

# Cyclization Reaction Optimization





Acid	Conditions			Yield (%)
	Method	Temp (°C)	Time	
<i>p</i> -TsOH	<b>Thermal</b>	<b>100</b>	<b>7 hrs</b>	<b>95</b>
	Microwave	160	5 min	61
Loose Si-TsOH	Thermal	100	6 hrs	84
	<b>Microwave</b>	<b>160</b>	<b>5 min</b>	<b>95</b>
Samplet Si-TsOH	Oven	110	64 hrs	38







# Parallel Enolate Reactions




70%




62%




67%




64%




66%




61%




89%




68%




95%



74%





89%




70%



# Parallel Cyclization Reactions



# Conclusion



	Microwave Assisted Synthesis			Conventional Synthesis		
	Temp (°C)	Time	Yield (%)	Temp (°C)	Time	Yield (%)
Step 1	160	10 min	95	100	2 hrs	60
Step 2 (Loose Si-TsOH)	160	5 min	95	100	7 hrs	84
<b>Total</b>	<b>-----</b>	<b>15 min</b>	<b>90</b>	<b>-----</b>	<b>9 hrs</b>	<b>50</b>



# Introduction to Encapsulated Pd

---

## Encapsulated Pd:-

- Use of microencapsulation technology to immobilize Pd, optionally with activating ligands, within a highly crosslinked polyurea matrix. The catalytic activity of Pd is accessed through the porous matrix, thereby leaving the Pd captured within it.

## Key Advantages of Encapsulated Pd:-

- Low residual metal levels in final crude product (typically < 10ppm before purification).
- Easy recovery of catalysts by filtration and catalyst recycle.
- Safer and easier to handle than Pd/C for hydrogenation reactions.
- Compatibility with a wide range of process technology options, *e.g.*, fixed bed, fluidized bed, trickle bed, and microwave reactors.





# Encapsulated Pd Products


---

- Pd EnCat 40:** (0.4 mmol/g) palladium acetate, microencapsulated in polyurea matrix.
- Pd EnCat 30:** (0.4 mmol/g) palladium acetate, microencapsulated in polyurea matrix. More porous version of Pd EnCat™ 40 with improved accessibility for substrates.
- Pd EnCat TPP30:** (0.4 mmol/g) palladium acetate & triphenyl phosphine, microencapsulated in polyurea matrix at 1/0.8 Pd/TPP.
- Pd EnCat TOTP30:** (0.4 mmol/g) palladium acetate & tri-*o*-tolylphosphine, microencapsulated in polyurea matrix at 1/0.5 Pd/TOTP.
-


# Initial Suzuki Couplings




**70%**




**60%**




**39%**



**15%**




**18%**



**3%**



# Exploration of EnCats & Ligands





Reaction Conditions	Catalyst	Yield (%)
a	Pd EnCat 40	12
a	Pd EnCat 30	8
a	Pd EnCat TPP30	12
a	Pd EnCat TOTP30	7
b*	Pd EnCat 40 + [( <sup>t</sup> Bu) <sub>3</sub> PH]BF <sub>4</sub>	8
b*	Pd EnCat 30 + [( <sup>t</sup> Bu) <sub>3</sub> PH]BF <sub>4</sub>	11


\*Fu, G. C. *et al. Org. Lett.* 2001, 3, 4295.




# Improved Conditions?




**17%**




**58%**




**64%**



**4%**



**51%**




**58%**





# Further Exploration of EnCats & Ligands




Reaction Conditions	Catalyst	Yield (%)
<b>a</b>	<b>Pd EnCat 40</b>	<b>51</b>
a	Pd EnCat 30	20
a	Pd EnCat TPP30	29
a	Pd EnCat TOTP30	6
b*	Pd EnCat 40 + [( <sup>t</sup> Bu) <sub>3</sub> PH]BF <sub>4</sub>	26
b*	Pd EnCat 30 + [( <sup>t</sup> Bu) <sub>3</sub> PH]BF <sub>4</sub>	32

\*Fu, G. C. *et al. Org. Lett.* 2001, 3, 4295.




# Pd EnCat vs Conventional Pd Catalysts



Temp (°C)	Catalyst	Time (hrs)	Yield (%)
50	$\text{Pd}_2(\text{dba})_3$	70	68
50 -> 75	Pd EnCat 40	94	29



# Microwave Irradiation Improvements



Temp (°C)	Solvent	Time (mins)	Yield (%)
<b>100</b>	<b>THF</b>	<b>15</b>	<b>100</b>
150	THF	5	51
150	MeCN	15	91
<b>150</b>	<b>MeCN</b>	<b>5</b>	<b>100</b>




# Conclusion

---

- Heterocyclic Suzuki, Heck & Sonogashira (results not shown) couplings using Pd EnCat catalysts occurred with significantly reduced yields when compared to traditional catalysts.
  - Application of microwave irradiation using  $\text{Pd}_2(\text{dba})_3 + [(\text{tBu})_3\text{PH}]\text{BF}_4$  (Fu's Salt) significantly reduced reaction time (70h  $\rightarrow$  5 min) of the Suzuki coupling reaction.
-



# Silica-bound cyanoborohydride-mediated reductive aminations




- Performed small array of analogues utilizing robot handler on Biotage Initiator 60.

- Utilized pre-weighed (from ASDI) aldehydes, supplied directly in μW vial.
- Dispensed template & solvent utilizing Tecan automated liquid handler.
- SPE "catch & release" treatment (utilizing SCX cartridges) of crude mixtures allowed for enhanced purification success & avoided LLE.




# Silica-bound carbodiimide-mediated amide bond formations



- Performed small array of analogues utilizing robot handler on Biotage Initiator 60.
- Utilized pre-weighed (from ASDI) acids, supplied directly in  $\mu\text{W}$  vial.
- Dispensed template & solvent utilizing Tecan automated liquid handler.
- SPE treatment (utilizing SAX cartridges) of crude mixtures allowed for enhanced purification success & avoided LLE.





# Elaboration of 2-Chloropyridines





# 2-Alkoxy-6-Aryloxy pyridines





- Late stage diversification of aryloxy moiety performs better than that of alkoxy, due to deactivation of resulting 2-chloropyridine intermediate.





# 2-Alkoxy-6-Amino & 6-Carboxamidopyridines



- Aminocarbonylation reaction performed better with '05 published conditions vs original conditions published in '03.

Genin, M. J. *et al. J. Med. Chem.* **1996**, *39*, 5267.

Kappe, C. O. *et al. J. Comb. Chem.* **2005**, *7*, 574.



# Acknowledgements

---

---

**Jennifer Finefield**

(Summer Intern - Celebrex)

**Aaron Clark**

(Summer Intern - Pd EnCat)

**Dave Wilhite**

(PGRD La Jolla - Project A & B)

**Quyen-Quyen Do**

(PGRD La Jolla - Project A & B)

**Shahnaz Ghassemi**

(Biotage - Celebrex & Piperidine)

**Ronny Lundin**

(Biotage - Pd EnCat)

**Pino Pilotti**

(Biotage - Pd EnCat)

---